This phase I dose escalation study enrolled pts with EGFR-negative stage IV NSCLC who were treated with platinum-based doublet previously. Pts received oral apatinib daily in a 3+3 dose escalation design (250, 500 and 750 mg) plus docetaxel at 60 mg/m² every 3 weeks. All 9 pts were available for response evaluation: 3 had partial response and 6 had stable disease, achieving an objective response rate of 33.3% and a disease control rate of 66.7%, at beast response. The median progression-free survival of 9 pts was 2.9 (95%CI, 1.7-3.3) mos. The preliminary results also demonstrated the efficacy of apatinib plus docetaxel in previously treated advanced NSCLC.